Table 1.
Characteristics at baseline of study population
| Characteristic | Total (n=31) |
Non-responder (n=11) |
Responder (n=20) |
P value |
| Age (years) | 68.4±7.1 | 72.2±4.0 | 66.3±7.6 | 0.026 |
| Male (%) | 19 (61) | 10 (91) | 9 (45) | 0.020 |
| Ischaemic aetiology—n (%) | 13 (42) | 7 (64) | 6 (30) | 0.128 |
| NYHA III—n (%) | 21 (69) | 10 (91) | 11 (55) | 0.055 |
| HF duration (months) | 16 (6–66) | 39 (14–66) | 13 (6–60) | 0.215 |
| Sinus rhythm—n (%) | 23 (82) | 8 (73) | 18 (90) | 0.224 |
| LBBB—n (%) | 26 (84) | 8 (80) | 18 (95) | 0.267 |
| QRS width (ms) | 154±17 | 157±21 | 153±15 | 0.556 |
| LVEF (%) | 26.6±8.1 | 24.5±8.6 | 27.7±7.7 | 0.298 |
| ACE/ARB—n (%) | 31 (100) | 11 (100) | 20 (100) | 1.000 |
| Beta blocker—n (%) | 28 (90) | 10 (91) | 18 (90) | 1.000 |
| VO2 peak (mL/kg/min) | 16.4±5.4 | 14.8±3.9 | 17.3±6.1 | 0.215 |
Values are presented as mean±SD, median with IQR, number or percentage.
ARB, angiotensin II receptor blocker; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VO2 peak, peak oxygen uptake capacity.